Peter Kolchinsky portfolio, Q2 2025

RA Capital Management · 13F for the quarter ending Jun 30, 2025

For Q2 2025, RA Capital Management reported $5.9B across 63 US-listed positions, led by ASND (29.9%), PCVX (6.6%) and RYTM (5.9%). Compared with its filing for Q1 2025, Peter Kolchinsky opened 6 new positions, added to 9, reduced 9 and sold out of 28; 39 positions did not change.

The largest purchase was an addition to Cidara Therapeutics Inc ($110.7M); the largest sale, the sale of the whole position in Apogee Therapeutics Inc ($58.6M).

Reported value
$5.9B
Positions
63
In the top 10
66%
Filed
Aug 14
2025

Key facts

13F portfolio value
$5.9BQ2 2025
Positions
63
Largest holding
ASND 29.9%
New positions
6
Sold out
28
Filed
Aug 14, 2025

Holdings as of (Q2 2025), filed with the SEC on . Changes are measured against the filing for Mar 31, 2025. Every tracked investor's Q2 2025 13F.

Bought and sold in Q2 2025

Peter Kolchinsky: buys and sells in Q2 2025
StockMoveSharesSizeOf portfolio
Cidara Therapeutics Incno ticker on file
▲ Added 208%+2.27M$110.7M1.87%
Apogee Therapeutics Incno ticker on file
▼ Sold out−1.57M$58.6M0.99%
Zai Lab LtdZLAB▼ Sold out−1.3M$46.8M0.79%
Day One Biopharmaceuticalsno ticker on file
▼ Sold out−5.76M$45.6M0.77%
UroGen Pharma LtdURGN▼ Sold out−3.21M$35.5M0.60%
Rhythm Pharmaceuticals IncRYTM▼ Reduced 8.6%−523.05K$33.1M0.56%
Taysha Gene Therapies IncTSHA▲ Added 117%+12.68M$29.3M0.49%
Avidity Biosciences Incno ticker on file
▲ Added 15%+965.62K$27.4M0.46%
Astria Therapeutics Incno ticker on file
▼ Sold out−5.11M$27.3M0.46%
Kura Oncology IncKURA▼ Sold out−4M$26.4M0.45%
Aerovate Therapeutics Incno ticker on file
▼ Sold out−9.19M$23.1M0.39%
IDEAYA Biosciences IncIDYA▼ Sold out−1.35M$22.1M0.37%
Iteos Therapeutics Incno ticker on file
▼ Sold out−3.65M$21.8M0.37%
Glaukos CorpGKOS▼ Sold out−190.26K$18.7M0.32%
Eyepoint Pharmaceuticals IncEYPT▼ Sold out−3.18M$17.2M0.29%
10X Genomics IncTXG▼ Reduced 76%−1.47M$17M0.29%
Ceribell IncCBLL▼ Sold out−824.58K$15.8M0.27%
Nurix Therapeutics IncNRIX▼ Sold out−1.33M$15.8M0.27%
Hinge Health IncHNGE▲ New+300K$15.5M0.26%
Insmed IncINSM▼ Sold out−200K$15.3M0.26%
Tyra Biosciences IncTYRA▲ Added 15%+1.56M$14.9M0.25%
Edgewise Therapeutics IncEWTX▲ Added 11%+993.54K$13M0.22%
MBX Biosciences IncMBX▼ Reduced 75%−1.13M$12.9M0.22%
Alector IncALEC▼ Sold out−9.7M$11.9M0.20%
Sera Prognostics IncSERA▼ Sold out−3.03M$11.2M0.19%
Jade Biosciences IncJBIO▲ New+1.06M$10.6M0.18%
Tango Therapeutics IncTNGX▲ New+2M$10.2M0.17%
Bicycle Therapeutics PlcBCYC▼ Sold out−1.09M$9.3M0.16%
GH Research PLCGHRS▲ Added 11%+732.05K$8.9M0.15%
Immatics N.V.IMTX▼ Sold out−1.75M$7.9M0.13%
Bright Minds Biosciences IncDRUG▼ Sold out−206.43K$7.4M0.13%
Omada Health IncOMDA▲ New+400K$7.3M0.12%
Vaxcyte IncPCVX▼ Reduced 1.8%−223.16K$7.3M0.12%
Solid Biosciences IncSLDB▲ Added 34%+1.48M$7.2M0.12%
Protara Therapeutics IncTARA▼ Reduced 69%−2.36M$7.2M0.12%
Aclaris Therapeutics IncACRS▼ Sold out−4.67M$7.1M0.12%
Xencor IncXNCR▼ Sold out−575K$6.1M0.10%
Humacyte IncHUMA▼ Sold out−3.31M$5.6M0.10%
GeneDx Holdings CorpWGS▲ New+58.04K$5.4M0.09%
Zura Bio LtdZURA▼ Sold out−3.22M$4.2M0.07%
Bioage Labs IncBIOA▼ Sold out−1.05M$4M0.07%
CytomX Therapeutics IncCTMX▲ Added 166%+1.66M$3.8M0.06%
Boundless Bio IncBOLD▼ Sold out−2.18M$3.3M0.06%
Acadia Healthcare CompanyACHC▼ Reduced 59%−127.74K$2.9M0.05%
Sutro BiopharmaSTRO▼ Sold out−4.43M$2.9M0.05%
Lexeo Therapeutics IncLXEO▼ Sold out−546.55K$1.9M0.03%
Inflarx NVIFRX▲ New+1.97M$1.6M0.03%
Surrozen IncSRZN▼ Reduced 11%−76.5K$683.9K0.01%
Werewolf Therapeutics IncHOWL▲ Added 8.7%+536.43K$584.7K0.01%
RxSight IncRXST▼ Reduced 1.1%−40.05K$520.7K0.01%
Scilex Holding Cono ticker on file
▼ Sold out−1.04M$257.5K0.00%
Avalo Therapeutics IncAVTX▼ Reduced 3.5%−34.03K$169.8K0.00%

Holdings at the quarter's end

Peter Kolchinsky holdings, Q2 2025
#StockSectorShare of portfolioValueSharesReported priceHeldSince Q1 2025
1Ascendis Pharma A/SASND · SPONSORED ADRHealth Care29.9%$1.8B10.28M$172.605+ qtrsNo change
2Vaxcyte IncPCVXHealth Care6.55%$389M11.97M$32.515+ qtrs▼ Reduced 1.8%
3Rhythm Pharmaceuticals IncRYTMHealth Care5.92%$351.4M5.56M$63.195+ qtrs▼ Reduced 8.6%
4Janux Therapeutics IncJANX—4.36%$258.5M11.19M$23.105+ qtrsNo change
5
Avidity Biosciences Incno ticker on file · SH
—3.48%$206.4M7.27M$28.405+ qtrs▲ Added 15%
6
Arcellx Incno ticker on file · SH
—3.37%$200M3.04M$65.855+ qtrsNo change
7
89BIO Incno ticker on file · SH
—3.29%$195.3M19.89M$9.825+ qtrsNo change
8Ars Pharmaceuticals IncSPRY—3.19%$189.5M10.86M$17.455+ qtrsNo change
9Newamsterdam Pharma CompanyNAMS—3.09%$183.6M10.14M$18.115+ qtrsNo change
10Sionna Therapeutics IncSION—3.05%$181.2M10.45M$17.352 qtrsNo change
11
Cidara Therapeutics Incno ticker on file · SH
—2.76%$163.9M3.37M$48.714 qtrs▲ Added 208%
12Edgewise Therapeutics IncEWTXHealth Care2.19%$129.8M9.9M$13.115+ qtrs▲ Added 11%
13Lenz Therapeutics IncLENZ—2.06%$122.5M4.18M$29.315+ qtrsNo change
14Wave Life Sciences LtdWVE—1.99%$118.3M18.2M$6.505+ qtrsNo change
15Tyra Biosciences IncTYRA—1.97%$116.7M12.2M$9.575+ qtrs▲ Added 15%
16GH Research PLCGHRS—1.58%$93.6M7.68M$12.195+ qtrs▲ Added 11%
17Dyne Therapeutics IncDYN · SH—1.56%$92.5M9.71M$9.525+ qtrsNo change
18Geron CorpGERN—1.43%$85.1M60.38M$1.415+ qtrsNo change
19Disc Medicine IncIRON—1.41%$83.5M1.58M$52.962 qtrsNo change
20Mineralys Therapeutics IncMLYS—1.40%$83.2M6.15M$13.535+ qtrsNo change
21Septerna IncSEPN—1.25%$73.9M7M$10.573 qtrsNo change
22Fulcrum Therapeutics IncFULC—1.19%$70.4M10.23M$6.885+ qtrsNo change
23Bicara Therapeutics IncBCAX—1.09%$64.6M6.96M$9.294 qtrsNo change
24Vor Biopharma IncVOR · SH—1.08%$64.2M39.65M$1.625+ qtrsNo change
25Taysha Gene Therapies IncTSHA—0.92%$54.4M23.56M$2.315+ qtrs▲ Added 117%
26Dianthus Therapeutics IncDNTHHealth Care0.90%$53.4M2.87M$18.635+ qtrsNo change
27RxSight IncRXST · SH—0.81%$48.1M3.7M$13.005+ qtrs▼ Reduced 1.1%
28
Tourmaline Bio Incno ticker on file · SH
—0.68%$40.6M2.54M$15.995+ qtrsNo change
29Scholar Rock Holding CorpSRRK · SHHealth Care0.68%$40.3M1.14M$35.423 qtrsNo change
30Climb Bio IncCLYM—0.66%$39M31.42M$1.245+ qtrsNo change
31Structure Therapeutics IncGPCR · SH—0.53%$31.5M1.52M$20.745+ qtrsNo change
32Solid Biosciences IncSLDB—0.48%$28.3M5.81M$4.875+ qtrs▲ Added 34%
33
Metsera Incno ticker on file · SH
—0.32%$19.2M675.53K$28.452 qtrsNo change
34Monopar Therapeutics IncMNPR—0.31%$18.3M511.21K$35.783 qtrsNo change
35Nkarta IncNKTX—0.30%$17.9M10.81M$1.665+ qtrsNo change
36Larimar Therapeutics IncLRMR · SH—0.29%$17.5M6.05M$2.895+ qtrsNo change
37Acumen Pharmaceuticals IncABOS—0.29%$17.3M14.93M$1.165+ qtrsNo change
38Enliven Therapeutics IncELVN · SH—0.29%$17M848.99K$20.065+ qtrsNo change
39Travere Therapeutics IncTVTXHealth Care0.29%$17M1.15M$14.803 qtrsNo change
404D Molecular TherapeuticsFDMT—0.29%$16.9M4.56M$3.715+ qtrsNo change
41Hinge Health IncHNGETechnology0.26%$15.5M300K$51.751 qtrNew
42Artiva Biotherapeutics IncARTV—0.25%$14.9M9.85M$1.514 qtrsNo change
43Pepgen IncPEPG—0.20%$11.9M10.69M$1.115+ qtrsNo change
44Jade Biosciences IncJBIO—0.18%$10.6M1.06M$9.991 qtrNew
45Tango Therapeutics IncTNGX · SH—0.17%$10.2M2M$5.121 qtrNew
46Acrivon Therapeutics IncACRV—0.17%$9.9M8.34M$1.195+ qtrsNo change
47Eledon Pharmaceuticals IncELDN · SH—0.16%$9.7M3.57M$2.713 qtrsNo change
48Arcus Biosciences IncRCUS · SH—0.16%$9.3M1.14M$8.142 qtrsNo change
49
Perceptive Cap Solutionsno ticker on file
—0.13%$8M750K$10.625+ qtrsNo change
50Omada Health IncOMDA · SH—0.12%$7.3M400K$18.301 qtrNew
51Werewolf Therapeutics IncHOWL—0.12%$7.3M6.68M$1.095+ qtrs▲ Added 8.7%
52Beta Bionics IncBBNX · SH—0.12%$7.3M500K$14.562 qtrsNo change
53CytomX Therapeutics IncCTMX · SH—0.10%$6M2.66M$2.272 qtrs▲ Added 166%
5410X Genomics IncTXG · SHHealth Care0.09%$5.5M475.34K$11.583 qtrs▼ Reduced 76%
55Surrozen IncSRZN · SH—0.09%$5.4M602.63K$8.945+ qtrs▼ Reduced 11%
56GeneDx Holdings CorpWGS—0.09%$5.4M58.04K$92.311 qtrNew
57Avalo Therapeutics IncAVTX—0.08%$4.7M932.97K$4.994 qtrs▼ Reduced 3.5%
58Adicet Bio IncACET · SH—0.08%$4.6M7.54M$0.61005+ qtrsNo change
59MBX Biosciences IncMBX · SH—0.07%$4.3M377.84K$11.414 qtrs▼ Reduced 75%
60Protara Therapeutics IncTARA · SH—0.05%$3.1M1.04M$3.035+ qtrs▼ Reduced 69%
61
Newamsterdam Pharma Co NV-27no ticker on file · WTS
—0.05%$2.7M333.33K$8.005+ qtrsNo change
62Acadia Healthcare CompanyACHC · SH—0.03%$2M89.26K$22.692 qtrs▼ Reduced 59%
63Inflarx NVIFRX · SH—0.03%$1.6M1.97M$0.79001 qtrNew

By sector

Peter Kolchinsky portfolio by sector, Q2 2025
SectorShare of portfolioValuePositions
Health Care46.5%$2.8B8
Technology0.26%$15.5M1
No sector on file53.2%$3.2B54

Questions and answers

What did Peter Kolchinsky own in Q2 2025?

RA Capital Management's 13F for Q2 2025 lists 63 positions worth $5.9B. The largest: ASND (29.9%), PCVX (6.6%), RYTM (5.9%), JANX (4.4%), Avidity Biosciences Inc (3.5%).

What did Peter Kolchinsky buy in Q2 2025?

The largest purchases, by the shares bought at the quarter-end price the filing implies: Cidara Therapeutics Inc (added, $110.7M), TSHA (added, $29.3M), Avidity Biosciences Inc (added, $27.4M), HNGE (new, $15.5M), TYRA (added, $14.9M), EWTX (added, $13M).

What did Peter Kolchinsky sell in Q2 2025?

The largest sales: Apogee Therapeutics Inc (sold out, $58.6M), ZLAB (sold out, $46.8M), Day One Biopharmaceuticals (sold out, $45.6M), URGN (sold out, $35.5M), RYTM (reduced, $33.1M), Astria Therapeutics Inc (sold out, $27.3M).

When was this filing made?

RA Capital Management filed its 13F for the quarter ending Jun 30, 2025 on Aug 14, 2025. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.

Learn

Cite this page

Funkfolio, “Peter Kolchinsky portfolio, Q2 2025: RA Capital Management 13F holdings”, data as of 14 August 2025. https://funkfolio.com/gurus/peter-kolchinsky/2025-q2

Underlying data: SEC EDGAR, Form 13F-HR of RA Capital Management (CIK 1346824) for the period ending Jun 30, 2025.

Source: SEC EDGAR, Form 13F-HR for RA Capital Management (CIK 1346824), period ending Jun 30, 2025, filed Aug 14, 2025. Changes compare share counts with the filing for Mar 31, 2025; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $5.9B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 5 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.